| P50 | author | Lars M. Ittner | Q30347436 |
| P2093 | author name string | Anne E Harasta | |
| P2860 | cites work | Caloric restriction attenuates Abeta-deposition in Alzheimer transgenic models | Q46142687 |
| | Therapeutic translation of iPSCs for treating neurological disease | Q46361862 |
| | Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. | Q46380915 |
| | Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. | Q46595342 |
| | Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. | Q46715173 |
| | Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice | Q46737335 |
| | Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography | Q46956780 |
| | ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease | Q47754186 |
| | Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice | Q47814284 |
| | Structure and novel exons of the human tau gene | Q48149325 |
| | One of the antigenic determinants of paired helical filaments is related to tau protein | Q48352721 |
| | Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition | Q48601482 |
| | Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease | Q48633197 |
| | An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". | Q48903618 |
| | Astrocytes contain amyloid-β annular protofibrils in Alzheimer's disease brains | Q48930597 |
| | Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease | Q49015193 |
| | Methylene blue by intraosseous infusion for methemoglobinemia. | Q50521019 |
| | Single App knock-in mouse models of Alzheimer's disease. | Q50670713 |
| | A 3D Alzheimer's disease culture model and the induction of P21-activated kinase mediated sensing in iPSC derived neurons. | Q50800388 |
| | An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. | Q53207278 |
| | Constitutive secretion of tau protein by an unconventional mechanism. | Q54306723 |
| | Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice | Q58028291 |
| | Protein phosphatase 2A dysfunction in Alzheimer's disease | Q21090465 |
| | Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE | Q22010705 |
| | Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease | Q22248076 |
| | Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers | Q22251089 |
| | Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein | Q22251280 |
| | beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology | Q22253223 |
| | Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein | Q24329019 |
| | Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain | Q24567623 |
| | Amyloid plaque core protein in Alzheimer disease and Down syndrome | Q24568384 |
| | Transmission and spreading of tauopathy in transgenic mouse brain | Q24651334 |
| | The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease | Q24656574 |
| | A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 |
| | Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease | Q24672501 |
| | Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice | Q24681736 |
| | Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease | Q27307877 |
| | Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1 | Q27314013 |
| | Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families | Q27860677 |
| | Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 |
| | Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex | Q37395157 |
| | The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells | Q37401120 |
| | Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice | Q37414108 |
| | Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain | Q37418341 |
| | Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2 | Q37524401 |
| | Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures | Q37552767 |
| | Neuronal activity regulates extracellular tau in vivo | Q37630201 |
| | The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives | Q37656554 |
| | Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease | Q37824813 |
| | Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 |
| | Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 |
| | Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein | Q28260479 |
| | Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host | Q28264821 |
| | Loss of apolipoprotein E receptor LR11 in Alzheimer disease | Q28277316 |
| | Posttranscriptional regulation of microRNA biogenesis in animals | Q28282519 |
| | Na, K-ATPase α3 is a death target of Alzheimer patient amyloid-β assembly. | Q28572007 |
| | Proteomic analysis of mitochondria in APOE transgenic mice and in response to an ischemic challenge | Q28730678 |
| | Animal models for Alzheimer's disease and frontotemporal dementia: a perspective | Q28749702 |
| | Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons | Q28771398 |
| | Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway | Q28854318 |
| | Impaired balance of mitochondrial fission and fusion in Alzheimer's disease | Q28854335 |
| | A specific amyloid-beta protein assembly in the brain impairs memory | Q28854597 |
| | Cerebral organoids model human brain development and microcephaly | Q28973619 |
| | Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 |
| | Regulation of mRNA translation and stability by microRNAs | Q29547304 |
| | Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction | Q29547778 |
| | Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein | Q29547803 |
| | Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease | Q29614374 |
| | Tau suppression in a neurodegenerative mouse model improves memory function | Q29615831 |
| | Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells | Q29615870 |
| | Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 |
| | Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease | Q29617986 |
| | Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden | Q30497435 |
| | Stem cell derived basal forebrain cholinergic neurons from Alzheimer's disease patients are more susceptible to cell death | Q30566020 |
| | Functional Genomics meets neurodegenerative disorders. Part II: application and data integration | Q31005421 |
| | Tau filament formation in transgenic mice expressing P301L tau. | Q31442641 |
| | Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the N-methyl-D-aspartate receptor | Q31451987 |
| | A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease | Q33292510 |
| | Oxidative stress and mitochondrial dysfunction in Alzheimer's disease | Q33555956 |
| | The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons | Q33725851 |
| | Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease | Q33732191 |
| | Accumulation of intraneuronal Abeta correlates with ApoE4 genotype | Q33771171 |
| | Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy | Q33920295 |
| | Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease | Q34002503 |
| | Stroke intervention pathways: NMDA receptors and beyond | Q34163807 |
| | Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity | Q34210006 |
| | Extrasynaptic NMDA receptor involvement in central nervous system disorders | Q34415681 |
| | Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes | Q34452028 |
| | Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration | Q34518577 |
| | The role of apolipoprotein E in Alzheimer's disease | Q34603092 |
| | A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity | Q34616539 |
| | Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses | Q34831241 |
| | Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. | Q34991746 |
| | The Alzheimer's associated 5' region of the SORL1 gene cis regulates SORL1 transcripts expression | Q35050752 |
| | Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer's disease donor as a model for investigating AD-associated gene regulatory networks | Q35132073 |
| | N-butylidenephthalide attenuates Alzheimer's disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons | Q35144310 |
| | Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers | Q35219340 |
| | Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells | Q35306023 |
| | microRNA-34c is a novel target to treat dementias | Q35422390 |
| | Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease | Q35532902 |
| | Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease | Q35711351 |
| | Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes | Q35794263 |
| | Differential interaction of Apolipoprotein-E isoforms with insulin receptors modulates brain insulin signaling in mutant human amyloid precursor protein transgenic mice | Q36034035 |
| | Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β | Q36054191 |
| | Functional interactions of tau and their relevance for Alzheimer's disease. | Q36173165 |
| | Alzheimer's disease models and functional genomics-How many needles are there in the haystack? | Q36193841 |
| | Differential calcium alterations in animal models of neurodegenerative disease: Reversal by FK506 | Q36248908 |
| | Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide | Q36384642 |
| | Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies | Q36466732 |
| | Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression | Q36609033 |
| | Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. | Q36630677 |
| | Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology | Q36724967 |
| | Environmental and dietary risk factors in Alzheimer's disease | Q36870079 |
| | Loss of progranulin function in frontotemporal lobar degeneration | Q37105126 |
| | Microtubule-associated protein tau in development, degeneration and protection of neurons | Q37151485 |
| | Animal models of Alzheimer's disease and frontotemporal dementia | Q37196122 |
| | The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation | Q37200468 |
| | Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease | Q37321251 |
| | Why size matters - balancing mitochondrial dynamics in Alzheimer's disease | Q38098662 |
| | Spreading of tau pathology in Alzheimer's disease by cell-to-cell transmission | Q38114938 |
| | New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease. | Q38149943 |
| | Downregulation of the microtubule associated protein tau impairs process outgrowth and myelin basic protein mRNA transport in oligodendrocytes | Q38890339 |
| | Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. | Q39173722 |
| | Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice | Q39398322 |
| | Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations | Q39506695 |
| | miR-29c regulates BACE1 protein expression | Q39544247 |
| | MicroRNA regulation of Alzheimer's Amyloid precursor protein expression. | Q39901302 |
| | Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons | Q39981187 |
| | Staging of Alzheimer's disease-related neurofibrillary changes | Q40416705 |
| | APP metabolism regulates tau proteostasis in human cerebral cortex neurons | Q40660550 |
| | Differential spontaneous transformation in vitro of newly established mouse fibroblast lines carrying or lacking the viable yellow mutation (Avy) of the mouse agouti locus | Q41255017 |
| | Alzheimer's disease-related amyloid-β induces synaptotoxicity in human iPS cell-derived neurons. | Q41984060 |
| | A three-dimensional human neural cell culture model of Alzheimer's disease | Q42069680 |
| | Tau is a candidate gene for chromosome 17 frontotemporal dementia | Q42456776 |
| | Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis | Q42467635 |
| | Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors | Q42491766 |
| | Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways | Q42584937 |
| | Modeling familial Alzheimer's disease with induced pluripotent stem cells | Q42817521 |
| | Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. | Q43271170 |
| | Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils | Q43718666 |
| | Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions | Q44193907 |
| | Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness | Q45736205 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 3-29 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Advances in neurobiology | Q27725720 |
| P1476 | title | Alzheimer's Disease: Insights from Genetic Mouse Models and Current Advances in Human IPSC-Derived Neurons | |
| P478 | volume | 15 | |